Meeker-O'Connell Ann, Sam Leslie M, Bergamo Nanci, Little Janis A
1 BioResearch Quality and Compliance, Johnson & Johnson, 1 Johnson and Johnson Plaza, New Brunswick, NJ, USA.
2 Global Quality Systems, Eli Lilly and Company, Indianapolis, IN, USA.
Ther Innov Regul Sci. 2016 Jul;50(4):397-413. doi: 10.1177/2168479016651300.
The Quality Management System (QMS) initiative of TransCelerate BioPharma Inc has identified potential benefits that could be captured from the development of a flexible, proactive clinical QMS conceptual framework for clinical research. Such a framework would aid organizations in seamlessly managing the complex clinical trial environment and, ultimately, in expediting delivery of needed treatments to patients. This article chronicles the evolution of a TransCelerate concept paper describing a proposed clinical QMS framework and reviews feedback from varied global clinical trial stakeholders during socialization of the concept paper. Many stakeholders recognized the potential for the concept paper to inform development of a harmonized International Council for Harmonisation (ICH) guideline, providing needed clarity from regulators on their expectations for QMS in the clinical realm. Accordingly, the article also describes TransCelerate's efforts to work with regulators to facilitate harmonization on this important topic and reviews ongoing work to develop additional tools and resources that may support organizations in evaluating whether and how they might translate the conceptual framework principles into practice.
TransCelerate生物制药公司的质量管理体系(QMS)倡议已经确定了从开发灵活、主动的临床研究临床QMS概念框架中可以获得的潜在益处。这样一个框架将帮助各组织无缝管理复杂的临床试验环境,并最终加快向患者提供所需治疗的速度。本文记录了一份描述拟议临床QMS框架的TransCelerate概念文件的演变过程,并回顾了在概念文件推广过程中来自全球不同临床试验利益相关者的反馈。许多利益相关者认识到该概念文件有可能为统一的国际协调理事会(ICH)指南的制定提供参考,使监管机构对其在临床领域对QMS的期望提供必要的明确说明。因此,本文还描述了TransCelerate与监管机构合作以促进在这一重要主题上的协调的努力,并回顾了正在进行的开发其他工具和资源的工作,这些工具和资源可能支持各组织评估它们是否以及如何将概念框架原则转化为实践。